Theranostics Revolution in Prostate Cancer: Basics, Clinical Applications, Open Issues and Future Perspectives
In the last decade, the therapeutic algorithm of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized with the advent of various therapeutic strategies that significantly improved patients' outcomes. Systemic options that have demonstrated a survival benefit in this setting include chemotherapy (e.g., docetaxel and cabazitaxel), androgen receptor-signaling inhibitors (ARSI; e.g., enzalutamide and abiraterone acetate), and Poly (ADP-ribose) polymerase (PARP) inhibitors (e.g., olaparib, rucaparib, and talazoparib), either alone or combined with an ARSi, in a selected cohort of tumors harboring HRR,...
Source: Cancer Treatment Reviews - February 10, 2024 Category: Cancer & Oncology Authors: Matteo Bauckneht, Chiara Ciccarese, Riccardo Laudicella, Claudia Mosillo, Francesca D'Amico, Annunziato Anghelone, Alessandro Strusi, Viria Beccia, Sergio Bracarda, Giuseppe Fornarini, Giampaolo Tortora, Roberto Iacovelli Tags: Hot Topic Source Type: research
Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India
ConclusionsWe concur with the inclusion of standard-dose AAP in India ’s publicly financed health insurance scheme for the intensification of treatment in mHSPC as it is the only cost-effective sequence among the various novel anti-androgens when compared with the docetaxel-first treatment sequence. Furthermore, a systematic reduction in the price of enzalutamide wo uld further help to improve clinical outcomes among patients with mHSPC. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - January 10, 2024 Category: Health Management Source Type: research
Concomitant antihypertensive medication and outcome of patients with metastatic castration ‐resistant prostate cancer receiving enzalutamide or abiraterone acetate
ConclusionThe findings of this study suggest an association between the concomitant use of ACEIs and longer survival of mCRPC patients receiving ENZ or ABI therapy. (Source: Cancer Medicine)
Source: Cancer Medicine - January 2, 2024 Category: Cancer & Oncology Authors: Ond řej Fiala,
Petr Hošek,
Hana Korunková,
Milan Hora,
Jiří Kolář,
Ondřej Šorejs,
Ondřej Topolčan,
Jan Filipovský,
Václav Liška,
Matteo Santoni,
Sebastiano Buti,
Jindřich Fínek Tags: RESEARCH ARTICLE Source Type: research
Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data
Breast. 2023 Dec 22;73:103667. doi: 10.1016/j.breast.2023.103667. Online ahead of print.ABSTRACTAntiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line wit...
Source: Breast - December 31, 2023 Category: Cancer & Oncology Authors: Yasmine Rhanine Herv é Bonnefoi Anthony Goncalves Marc Debled Sylvestre Le Moulec Nathalie Bonichon Gaetan Macgrogan Monica Arnedos B énédicte Dubroca-Dehez Thomas Grellety Source Type: research
Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data
Breast. 2023 Dec 22;73:103667. doi: 10.1016/j.breast.2023.103667. Online ahead of print.ABSTRACTAntiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line wit...
Source: Breast - December 31, 2023 Category: Cancer & Oncology Authors: Yasmine Rhanine Herv é Bonnefoi Anthony Goncalves Marc Debled Sylvestre Le Moulec Nathalie Bonichon Gaetan Macgrogan Monica Arnedos B énédicte Dubroca-Dehez Thomas Grellety Source Type: research
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects
ConclusionsThe abiraterone exposures of 250 mg SUVN-1105 in the fasted or fed conditions fall within the abiraterone exposures of 1000 mg Zytiga in fasted and modified fasted conditions. Single doses of SUVN-1105 were safe and well-tolerated in healthy males both in the fasted and fed conditions. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - December 29, 2023 Category: Cancer & Oncology Source Type: research
PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
Conclusion: Our results demonstrate that PSMA PET/CT is a valuable imaging biomarker for response assessment and overall survival prediction when performed at 3 mo after ARPI treatment initiation in mCRPC patients. Both proposed PSMA response criteria (EAU/EANM and RECIP 1.0) seem to perform equally well. No PSMA flare was observed. Prospective validation of these findings is strongly needed. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Shagera, Q. A., Karfis, I., Kristanto, P., Spyridon, S., Diamand, R., Santapau, A., Peltier, A., Roumeguere, T., Flamen, P., Artigas, C. Tags: Clinical Investigations Source Type: research
HTA157 Reflection on Medicines That Have Recently Come Off Patent and Have Been Rejected by NICE in the Past 20 Years: A Case Study of Abiraterone for Treating Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (MHSPC)
Abiraterone is a drug used for treating metastatic hormone sensitive prostate cancer (mHSPC). The combination of Abiraterone Acetate plus Prednisone (AAP) with the standard Androgen Deprivation Therapy (ADT) showed a better clinical outcome. Abiraterone received a negative recommendation from the National Institute for Health and Care Excellence (NICE) in 2021 due to its high cost. The cost of Abiraterone is expected to decrease after the brand's patent expires in September 2022 and this is anticipated to affect NICE ’s decision. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: O. Madani Source Type: research
Cancers, Vol. 15, Pages 5333: The Geriatric Nutritional Risk Index Predicts Prognosis in Japanese Patients with LATITUDE High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Multi-Center Study
This study included a total of 175 patients with LATITUDE high-risk mHSPC, of whom 102 had received androgen deprivation therapy (ADT) plus upfront abiraterone acetate, and 73 had received ADT plus bicalutamide (Bica), from 14 institutions associated with the Tokai Urologic Oncology Research Seminar. Patients were classified into GNRI-low (<98) or GNRI-high (≥98) groups. The GNRI was based on the body mass index and serum albumin level. Kaplan–Meier analysis revealed that the median overall survival (OS) of a GNRI-low group (median 33.7 months; 95% confidence interval [CI]: 26.2&...
Source: Cancers - November 8, 2023 Category: Cancer & Oncology Authors: Taku Naiki Kiyoshi Takahara Hiromitsu Watanabe Keita Nakane Yosuke Sugiyama Takuya Koie Ryoichi Shiroki Hideaki Miyake Takahiro Yasui Tags: Article Source Type: research
Cancers, Vol. 15, Pages 5273: Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer
Liu
Allen C. Gao
Current common treatments for castration-resistant prostate cancer (CRPC) typically belong to one of three major categories: next-generation anti-androgen therapies (NGAT) including enzalutamide, abiraterone acetate, apalutamide, and darolutamide; taxane therapy represented by docetaxel; and PARP inhibitors (PARPi) like olaparib. Although these treatments have shown efficacy and have improved outcomes for many patients, some do not survive due to the emergence of therapeutic resistance. The clinical landscape is further complicated by limited knowledge about how the sequence of treatments impacts th...
Source: Cancers - November 3, 2023 Category: Cancer & Oncology Authors: Zachary A. Schaaf Shu Ning Amy R. Leslie Masuda Sharifi Xianrui Han Cameron Armstrong Wei Lou Alan P. Lombard Chengfei Liu Allen C. Gao Tags: Article Source Type: research
Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate
ConclusionOur study shows that cortisol is not an independent predictor of abiraterone response in patients with mCRPC, but it is of added value in combination with abiraterone levels, to predict a response on abiraterone. (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - October 11, 2023 Category: Drugs & Pharmacology Source Type: research
Cost-Effectiveness Analysis for Therapy Sequence in Advanced Cancer: A Microsimulation Approach with Application to Metastatic Prostate Cancer
CONCLUSIONS: We demonstrate a microsimulation approach to study the cost-effectiveness of therapy sequences for advanced prostate cancer, taking care to account for within-patient dependence.HIGHLIGHTS: We developed a discrete-time state transition model for studying therapy sequence in advanced cancers.Results are sensitive to dependence within patients.A calibration approach can introduce dependence across lines of therapy and closely match simulation outcomes to target trial outcomes.PMID:37811793 | DOI:10.1177/0272989X231201621 (Source: Cancer Control)
Source: Cancer Control - October 9, 2023 Category: Cancer & Oncology Authors: Elizabeth A Handorf J Robert Beck Andres Correa Chethan Ramamurthy Daniel M Geynisman Source Type: research
Outcomes and toxicity of oral Fosfestrol in metastatic castration-resistant prostate cancer-a real-world experience
CONCLUSION: We conclude that oral Fosfestrol is a cheap and effective agent in the armamentarium against metastatic CRPC and warrants further studies in a clinical trial setting.PMID:37799959 | PMC:PMC10550288 | DOI:10.3332/ecancer.2023.1589 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - October 6, 2023 Category: Cancer & Oncology Authors: R Nandini Devi V P Praveen Kumar Shenoy Irshad Ismail Manuprasad Avaronnan Source Type: research
